You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

 

Online download statistics by month:

Online download statistics by month: January 2024 to February 2026

AbstractFullPdf
Jan 202414815345
Feb 2024632635247
Mar 2024162165117
Apr 20249810078
May 2024939561
Jun 2024969751
Jul 2024888852
Aug 2024686843
Sep 2024676936
Oct 2024838348
Nov 202411111260
Dec 2024818343
Jan 2025140140101
Feb 202523223459
Mar 2025999971
Apr 202511111151
May 2025757636
Jun 2025737334
Jul 2025220
Aug 2025110
Feb 2026110
Total246124851233